Protocol No.: MK1084-007

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
Principal Investigator
Bhasin, Pooja Gogia
Phase
III
Age Group
Adult
Applicable Disease Site
Lung Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Rachel Harper
Clinical Research Specialist
Phone: +1 304-293-6066

View on ClinicalTrials.gov